| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endometrial Neoplasms | 14 | 2020 | 1341 | 0.940 |
Why?
|
| Ovarian Neoplasms | 27 | 2020 | 4638 | 0.910 |
Why?
|
| Metformin | 6 | 2018 | 378 | 0.600 |
Why?
|
| Obesity | 5 | 2018 | 2884 | 0.380 |
Why?
|
| Cystadenocarcinoma, Serous | 3 | 2013 | 486 | 0.350 |
Why?
|
| Endometrium | 4 | 2018 | 470 | 0.320 |
Why?
|
| Hypoglycemic Agents | 3 | 2016 | 586 | 0.290 |
Why?
|
| Omentum | 2 | 2020 | 96 | 0.280 |
Why?
|
| Receptor, EphA2 | 4 | 2009 | 132 | 0.270 |
Why?
|
| Carcinoma, Endometrioid | 3 | 2016 | 323 | 0.270 |
Why?
|
| Proto-Oncogene Proteins c-abl | 2 | 2004 | 79 | 0.240 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2006 | 1756 | 0.240 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 2 | 2003 | 153 | 0.230 |
Why?
|
| Gene Expression Regulation, Neoplastic | 12 | 2020 | 8873 | 0.220 |
Why?
|
| Kallikreins | 1 | 2003 | 84 | 0.220 |
Why?
|
| Ovary | 3 | 2020 | 668 | 0.220 |
Why?
|
| Lectins | 2 | 2020 | 151 | 0.220 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2004 | 479 | 0.210 |
Why?
|
| Neovascularization, Pathologic | 7 | 2011 | 1547 | 0.200 |
Why?
|
| PTEN Phosphohydrolase | 3 | 2016 | 986 | 0.200 |
Why?
|
| Everolimus | 2 | 2021 | 415 | 0.200 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2011 | 1362 | 0.190 |
Why?
|
| Cell Line, Tumor | 20 | 2020 | 14551 | 0.190 |
Why?
|
| Estradiol | 3 | 2017 | 748 | 0.180 |
Why?
|
| Stromal Cells | 2 | 2016 | 825 | 0.180 |
Why?
|
| Biomarkers, Tumor | 7 | 2016 | 10331 | 0.180 |
Why?
|
| Cyclopentanes | 1 | 2020 | 40 | 0.180 |
Why?
|
| RNA, Small Interfering | 6 | 2013 | 2216 | 0.180 |
Why?
|
| ras Proteins | 2 | 2014 | 770 | 0.170 |
Why?
|
| RNA Interference | 3 | 2009 | 1408 | 0.170 |
Why?
|
| Immunohistochemistry | 13 | 2017 | 7548 | 0.170 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2014 | 2488 | 0.170 |
Why?
|
| Adenosine Triphosphatases | 2 | 2013 | 435 | 0.170 |
Why?
|
| Endometrial Hyperplasia | 2 | 2016 | 112 | 0.160 |
Why?
|
| DNA Mismatch Repair | 1 | 2020 | 268 | 0.160 |
Why?
|
| Healthy Lifestyle | 1 | 2018 | 44 | 0.160 |
Why?
|
| Female | 45 | 2022 | 141928 | 0.150 |
Why?
|
| MAP Kinase Kinase 2 | 1 | 2017 | 44 | 0.150 |
Why?
|
| Cell Proliferation | 13 | 2020 | 7226 | 0.150 |
Why?
|
| Drug Delivery Systems | 1 | 2021 | 669 | 0.150 |
Why?
|
| Weight Reduction Programs | 1 | 2018 | 78 | 0.150 |
Why?
|
| Carcinoma | 3 | 2013 | 2578 | 0.140 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2017 | 160 | 0.140 |
Why?
|
| Apoptotic Protease-Activating Factor 1 | 1 | 2016 | 38 | 0.140 |
Why?
|
| Proteome | 1 | 2020 | 561 | 0.140 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2014 | 1265 | 0.130 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 3 | 2017 | 1331 | 0.130 |
Why?
|
| Xenograft Model Antitumor Assays | 7 | 2020 | 3821 | 0.130 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 2 | 2006 | 161 | 0.130 |
Why?
|
| RNA, Messenger | 5 | 2014 | 6150 | 0.130 |
Why?
|
| Neoplasm Proteins | 1 | 2006 | 3230 | 0.130 |
Why?
|
| Pyrimidines | 3 | 2020 | 3518 | 0.120 |
Why?
|
| Estrogen Receptor alpha | 2 | 2017 | 701 | 0.120 |
Why?
|
| Gene Amplification | 2 | 2008 | 731 | 0.120 |
Why?
|
| Influenza, Human | 1 | 2022 | 925 | 0.120 |
Why?
|
| Alzheimer Disease | 1 | 2022 | 855 | 0.120 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2014 | 131 | 0.120 |
Why?
|
| Cytokines | 2 | 2020 | 2809 | 0.120 |
Why?
|
| Peritoneal Neoplasms | 1 | 2020 | 821 | 0.110 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 4 | 1 | 2013 | 27 | 0.110 |
Why?
|
| Exosomes | 1 | 2016 | 253 | 0.110 |
Why?
|
| Streptozocin | 1 | 2013 | 75 | 0.110 |
Why?
|
| Antineoplastic Agents | 9 | 2021 | 14289 | 0.110 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2016 | 5178 | 0.110 |
Why?
|
| Hyperinsulinism | 1 | 2013 | 85 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 8 | 2014 | 3639 | 0.110 |
Why?
|
| Body Weight | 1 | 2016 | 1293 | 0.100 |
Why?
|
| Membrane Transport Proteins | 1 | 2013 | 244 | 0.100 |
Why?
|
| Receptors, Progesterone | 4 | 2017 | 1392 | 0.100 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2013 | 299 | 0.100 |
Why?
|
| Paclitaxel | 2 | 2016 | 1996 | 0.100 |
Why?
|
| Apoptosis | 10 | 2016 | 7591 | 0.100 |
Why?
|
| Humans | 41 | 2022 | 261506 | 0.100 |
Why?
|
| Adipose Tissue | 2 | 2016 | 769 | 0.100 |
Why?
|
| Animals | 19 | 2021 | 59536 | 0.090 |
Why?
|
| Liposomes | 3 | 2006 | 684 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2010 | 80 | 0.090 |
Why?
|
| Mutation | 6 | 2020 | 15179 | 0.090 |
Why?
|
| Aptamers, Nucleotide | 1 | 2010 | 62 | 0.090 |
Why?
|
| Cisplatin | 3 | 2013 | 2432 | 0.090 |
Why?
|
| Sirolimus | 1 | 2014 | 814 | 0.090 |
Why?
|
| Pericytes | 1 | 2010 | 96 | 0.090 |
Why?
|
| Estrous Cycle | 1 | 2009 | 37 | 0.090 |
Why?
|
| Mice | 15 | 2020 | 34495 | 0.090 |
Why?
|
| Mice, Nude | 7 | 2010 | 4307 | 0.080 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2014 | 3552 | 0.080 |
Why?
|
| Genetic Therapy | 2 | 2006 | 1616 | 0.080 |
Why?
|
| Endoribonucleases | 1 | 2008 | 107 | 0.080 |
Why?
|
| GPI-Linked Proteins | 2 | 2020 | 223 | 0.080 |
Why?
|
| Ribonuclease III | 1 | 2008 | 182 | 0.080 |
Why?
|
| Cation Transport Proteins | 1 | 2009 | 199 | 0.080 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2014 | 1546 | 0.070 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2010 | 461 | 0.070 |
Why?
|
| Oligopeptides | 1 | 2009 | 429 | 0.070 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2008 | 255 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 4 | 2020 | 3981 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2008 | 311 | 0.070 |
Why?
|
| Enzyme Inhibitors | 2 | 2004 | 1879 | 0.070 |
Why?
|
| Epithelial Cells | 2 | 2004 | 1818 | 0.070 |
Why?
|
| Thromboplastin | 1 | 2005 | 34 | 0.070 |
Why?
|
| Immunoconjugates | 1 | 2009 | 279 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 4 | 2010 | 5395 | 0.070 |
Why?
|
| Receptor, Notch1 | 1 | 2007 | 218 | 0.070 |
Why?
|
| Phosphatidylinositol 3-Kinases | 3 | 2021 | 1678 | 0.070 |
Why?
|
| Down-Regulation | 4 | 2020 | 2074 | 0.070 |
Why?
|
| Gene Silencing | 3 | 2013 | 837 | 0.060 |
Why?
|
| In Situ Hybridization | 2 | 2006 | 1037 | 0.060 |
Why?
|
| Estrogens | 1 | 2009 | 751 | 0.060 |
Why?
|
| Piperazines | 2 | 2004 | 2101 | 0.060 |
Why?
|
| Immunoenzyme Techniques | 3 | 2014 | 1165 | 0.060 |
Why?
|
| MicroRNAs | 2 | 2016 | 2947 | 0.060 |
Why?
|
| Cloning, Molecular | 1 | 2006 | 1213 | 0.060 |
Why?
|
| Cadherins | 1 | 2007 | 660 | 0.060 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2008 | 519 | 0.060 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2004 | 107 | 0.060 |
Why?
|
| Cell Movement | 3 | 2020 | 2466 | 0.060 |
Why?
|
| Rats, Zucker | 2 | 2014 | 60 | 0.060 |
Why?
|
| Mixed Tumor, Mullerian | 1 | 2003 | 37 | 0.060 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2004 | 153 | 0.060 |
Why?
|
| Rats | 3 | 2021 | 6086 | 0.060 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2006 | 2232 | 0.060 |
Why?
|
| Gene Expression Profiling | 5 | 2013 | 5159 | 0.060 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2010 | 1248 | 0.060 |
Why?
|
| Incidence | 2 | 2011 | 5673 | 0.060 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 2003 | 82 | 0.060 |
Why?
|
| Blotting, Northern | 1 | 2003 | 682 | 0.050 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2020 | 2359 | 0.050 |
Why?
|
| Imatinib Mesylate | 2 | 2004 | 1665 | 0.050 |
Why?
|
| Receptors, Estrogen | 2 | 2007 | 2086 | 0.050 |
Why?
|
| Taxoids | 1 | 2005 | 967 | 0.050 |
Why?
|
| Phosphatidylcholines | 3 | 2006 | 144 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2021 | 2054 | 0.050 |
Why?
|
| Benzamides | 2 | 2004 | 1832 | 0.050 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2005 | 852 | 0.050 |
Why?
|
| Epithelium | 1 | 2003 | 720 | 0.050 |
Why?
|
| Peptides | 1 | 2007 | 1479 | 0.050 |
Why?
|
| Ki-67 Antigen | 2 | 2016 | 666 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 3 | 2010 | 4367 | 0.050 |
Why?
|
| Cytoskeletal Proteins | 1 | 2003 | 492 | 0.050 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2020 | 58 | 0.050 |
Why?
|
| NEDD8 Protein | 1 | 2020 | 22 | 0.050 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2021 | 265 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2004 | 2508 | 0.050 |
Why?
|
| Polymers | 1 | 2021 | 223 | 0.050 |
Why?
|
| Lactoferrin | 1 | 2020 | 81 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2007 | 1586 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 1 | 2007 | 1491 | 0.040 |
Why?
|
| HCT116 Cells | 1 | 2020 | 348 | 0.040 |
Why?
|
| Carcinoma, Papillary | 1 | 2003 | 584 | 0.040 |
Why?
|
| Protein Stability | 1 | 2020 | 370 | 0.040 |
Why?
|
| Blotting, Western | 3 | 2009 | 3536 | 0.040 |
Why?
|
| Uterine Neoplasms | 1 | 2003 | 545 | 0.040 |
Why?
|
| Insulin | 2 | 2016 | 1454 | 0.040 |
Why?
|
| Prognosis | 7 | 2014 | 21713 | 0.040 |
Why?
|
| Propensity Score | 1 | 2022 | 750 | 0.040 |
Why?
|
| Risk Factors | 2 | 2016 | 17523 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2006 | 1489 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2010 | 1533 | 0.040 |
Why?
|
| Neoplasm Staging | 6 | 2013 | 13658 | 0.040 |
Why?
|
| Microsatellite Instability | 1 | 2020 | 400 | 0.040 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2009 | 448 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2010 | 1062 | 0.040 |
Why?
|
| Transplantation, Heterologous | 2 | 2011 | 1082 | 0.040 |
Why?
|
| Cell Survival | 3 | 2009 | 3045 | 0.040 |
Why?
|
| Uterus | 1 | 2021 | 678 | 0.040 |
Why?
|
| Middle Aged | 9 | 2022 | 86204 | 0.040 |
Why?
|
| Immunoprecipitation | 2 | 2009 | 591 | 0.040 |
Why?
|
| Trans-Activators | 1 | 2003 | 1555 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2007 | 2819 | 0.030 |
Why?
|
| Adiposity | 1 | 2018 | 237 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2022 | 1819 | 0.030 |
Why?
|
| Adiponectin | 1 | 2016 | 163 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2016 | 259 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2013 | 2307 | 0.030 |
Why?
|
| Tumor Burden | 2 | 2013 | 1987 | 0.030 |
Why?
|
| Vaccination | 1 | 2022 | 1123 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2016 | 471 | 0.030 |
Why?
|
| Pyrimidinones | 1 | 2017 | 314 | 0.030 |
Why?
|
| Body Composition | 1 | 2018 | 595 | 0.030 |
Why?
|
| Leptin | 1 | 2016 | 295 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2010 | 15862 | 0.030 |
Why?
|
| Pyridones | 1 | 2017 | 348 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2020 | 2927 | 0.030 |
Why?
|
| Biomarkers | 2 | 2018 | 5047 | 0.030 |
Why?
|
| Adipocytes | 1 | 2016 | 305 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2020 | 7222 | 0.030 |
Why?
|
| Weight Loss | 1 | 2018 | 627 | 0.030 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2016 | 413 | 0.030 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2016 | 630 | 0.030 |
Why?
|
| R-SNARE Proteins | 1 | 2013 | 18 | 0.030 |
Why?
|
| Qa-SNARE Proteins | 1 | 2013 | 37 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2020 | 1048 | 0.030 |
Why?
|
| Aged | 7 | 2022 | 70117 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2017 | 848 | 0.030 |
Why?
|
| Proto-Oncogenes | 1 | 2013 | 202 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2022 | 9244 | 0.030 |
Why?
|
| Adult | 7 | 2022 | 77950 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2018 | 12873 | 0.030 |
Why?
|
| Golgi Apparatus | 1 | 2013 | 147 | 0.030 |
Why?
|
| DNA Methylation | 2 | 2014 | 2669 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2020 | 4143 | 0.030 |
Why?
|
| Protein Kinase C | 1 | 2013 | 396 | 0.030 |
Why?
|
| Protein Transport | 1 | 2013 | 734 | 0.020 |
Why?
|
| Transfection | 2 | 2008 | 2944 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2016 | 1152 | 0.020 |
Why?
|
| Subcutaneous Fat | 1 | 2011 | 92 | 0.020 |
Why?
|
| Fluorescent Dyes | 1 | 2013 | 459 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2018 | 2203 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 2864 | 0.020 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2010 | 160 | 0.020 |
Why?
|
| Copper-transporting ATPases | 1 | 2009 | 44 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2013 | 850 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2014 | 1742 | 0.020 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2009 | 157 | 0.020 |
Why?
|
| Up-Regulation | 2 | 2007 | 2450 | 0.020 |
Why?
|
| Treatment Outcome | 4 | 2018 | 32848 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2016 | 1682 | 0.020 |
Why?
|
| Multivariate Analysis | 2 | 2008 | 4298 | 0.020 |
Why?
|
| Signal Transduction | 3 | 2013 | 11965 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2020 | 6942 | 0.020 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2010 | 245 | 0.020 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2009 | 195 | 0.020 |
Why?
|
| DNA Adducts | 1 | 2009 | 210 | 0.020 |
Why?
|
| Microvessels | 1 | 2009 | 135 | 0.020 |
Why?
|
| DNA Primers | 1 | 2010 | 1399 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2014 | 3203 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2014 | 1375 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2010 | 769 | 0.020 |
Why?
|
| Hormone Replacement Therapy | 1 | 2009 | 205 | 0.020 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2008 | 301 | 0.020 |
Why?
|
| Survival Rate | 1 | 2020 | 12221 | 0.020 |
Why?
|
| Dimerization | 1 | 2007 | 304 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2020 | 3341 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2009 | 639 | 0.020 |
Why?
|
| HLA-A2 Antigen | 1 | 2007 | 159 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2009 | 1008 | 0.020 |
Why?
|
| Ascites | 1 | 2007 | 198 | 0.020 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2007 | 360 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2010 | 938 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2014 | 3154 | 0.020 |
Why?
|
| Cellular Senescence | 1 | 2008 | 382 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 2008 | 771 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2010 | 891 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2011 | 3033 | 0.020 |
Why?
|
| Cell Line | 1 | 2013 | 5114 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2006 | 886 | 0.020 |
Why?
|
| Binding Sites | 1 | 2009 | 2171 | 0.020 |
Why?
|
| Gene Expression | 1 | 2013 | 3570 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2010 | 1945 | 0.020 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2004 | 104 | 0.020 |
Why?
|
| Colorectal Neoplasms | 1 | 2020 | 3578 | 0.020 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2007 | 589 | 0.010 |
Why?
|
| Paraffin Embedding | 1 | 2004 | 226 | 0.010 |
Why?
|
| Mesna | 1 | 2003 | 65 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2007 | 1258 | 0.010 |
Why?
|
| Base Sequence | 1 | 2010 | 4917 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2008 | 1152 | 0.010 |
Why?
|
| Caspases | 1 | 2005 | 661 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2007 | 1021 | 0.010 |
Why?
|
| Exons | 1 | 2006 | 1328 | 0.010 |
Why?
|
| Ifosfamide | 1 | 2003 | 344 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2008 | 2283 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2004 | 756 | 0.010 |
Why?
|
| Age Distribution | 1 | 2004 | 698 | 0.010 |
Why?
|
| Protein Binding | 1 | 2009 | 3438 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2008 | 1130 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2008 | 2084 | 0.010 |
Why?
|
| GTP Phosphohydrolases | 1 | 2004 | 336 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2017 | 4757 | 0.010 |
Why?
|
| Cell Lineage | 1 | 2004 | 668 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2011 | 4078 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2007 | 4233 | 0.010 |
Why?
|
| Endothelial Cells | 1 | 2007 | 1048 | 0.010 |
Why?
|
| Protein Array Analysis | 1 | 2003 | 501 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2007 | 6089 | 0.010 |
Why?
|
| RNA | 1 | 2004 | 1013 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2004 | 2316 | 0.010 |
Why?
|
| beta Catenin | 1 | 2003 | 688 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2008 | 6207 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2010 | 3251 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2010 | 8865 | 0.010 |
Why?
|
| Aged, 80 and over | 2 | 2008 | 29902 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2003 | 1620 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2005 | 4892 | 0.010 |
Why?
|
| Logistic Models | 1 | 2004 | 3441 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2004 | 4804 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2004 | 4971 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2007 | 4821 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2004 | 6100 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2005 | 9180 | 0.010 |
Why?
|
| Receptor, ErbB-2 | 1 | 2003 | 2518 | 0.010 |
Why?
|
| Male | 1 | 2022 | 123000 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2004 | 6869 | 0.010 |
Why?
|
| United States | 1 | 2004 | 15433 | 0.000 |
Why?
|
| Lung Neoplasms | 1 | 2008 | 11538 | 0.000 |
Why?
|
| Breast Neoplasms | 1 | 2008 | 15694 | 0.000 |
Why?
|
| Neoplasms | 1 | 2004 | 15193 | 0.000 |
Why?
|